205 related articles for article (PubMed ID: 27525431)
41. Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?
Perić B; Kruljac I; Šundalić S; Pećina HI; Jović A; Štefanović M; Butorac D; Vrkljan M
Endocr Res; 2016 Aug; 41(3):200-6. PubMed ID: 26864960
[TBL] [Abstract][Full Text] [Related]
42. Effect of cabergoline on metabolism in prolactinomas.
Auriemma RS; Granieri L; Galdiero M; Simeoli C; Perone Y; Vitale P; Pivonello C; Negri M; Mannarino T; Giordano C; Gasperi M; Colao A; Pivonello R
Neuroendocrinology; 2013; 98(4):299-310. PubMed ID: 24355865
[TBL] [Abstract][Full Text] [Related]
43. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C
J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167
[TBL] [Abstract][Full Text] [Related]
44. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
Gillam MP; Middler S; Freed DJ; Molitch ME
J Clin Endocrinol Metab; 2002 Oct; 87(10):4447-51. PubMed ID: 12364416
[TBL] [Abstract][Full Text] [Related]
45. Long-term outcome of macroprolactinomas.
Képénékian L; Cebula H; Castinetti F; Graillon T; Brue T; Goichot B
Ann Endocrinol (Paris); 2016 Dec; 77(6):641-648. PubMed ID: 27641080
[TBL] [Abstract][Full Text] [Related]
46. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.
Greenman Y; Tordjman K; Stern N
Clin Endocrinol (Oxf); 1998 May; 48(5):547-53. PubMed ID: 9666865
[TBL] [Abstract][Full Text] [Related]
47. LHRH-induced gonadotropin release before and after short-term therapy with cabergoline in hyperprolactinaemic patients.
Durante R; Giusti M; Carraro A; Porcella E
Minerva Endocrinol; 1991; 16(1):11-6. PubMed ID: 1944011
[TBL] [Abstract][Full Text] [Related]
48. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
De Rosa M; Ciccarelli A; Zarrilli S; Guerra E; Gaccione M; Di Sarno A; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2006 Mar; 64(3):307-13. PubMed ID: 16487441
[TBL] [Abstract][Full Text] [Related]
49. The influence of other than prolactin hormones on bone mineral density in women with hyperprolactinaemia of various origins.
Bolanowski M; Zadrozna-Sliwka B; Jawiarczyk A; Syrycka J
Gynecol Endocrinol; 2010 Aug; 26(8):623-7. PubMed ID: 20218822
[TBL] [Abstract][Full Text] [Related]
50. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
dos Santos Silva CM; Barbosa FR; Lima GA; Warszawski L; Fontes R; Domingues RC; Gadelha MR
Obesity (Silver Spring); 2011 Apr; 19(4):800-5. PubMed ID: 20559294
[TBL] [Abstract][Full Text] [Related]
51. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
52. Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist.
Shiraishi J; Koyama H; Shirakawa M; Ishikura R; Okazaki H; Kurajoh M; Shoji T; Moriwaki Y; Yamamoto T; Namba M
Intern Med; 2016; 55(8):935-41. PubMed ID: 27086808
[TBL] [Abstract][Full Text] [Related]
53. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Rains CP; Bryson HM; Fitton A
Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
[TBL] [Abstract][Full Text] [Related]
54. Pregnancy and Tumor Outcomes in Women with Prolactinoma.
Araujo B; Belo S; Carvalho D
Exp Clin Endocrinol Diabetes; 2017 Nov; 125(10):642-648. PubMed ID: 28704852
[No Abstract] [Full Text] [Related]
55. Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists.
Al Dahmani KM; Almalki MH; Ekhzaimy A; Aziz F; Bashier A; Mahzari MM; Beshyah SA
Pituitary; 2022 Aug; 25(4):658-666. PubMed ID: 35793046
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
57. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.
Gibson CD; Karmally W; McMahon DJ; Wardlaw SL; Korner J
Diabetes Obes Metab; 2012 Apr; 14(4):335-40. PubMed ID: 22074059
[TBL] [Abstract][Full Text] [Related]
58. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
[TBL] [Abstract][Full Text] [Related]
59. NUTRITIONAL AND METABOLIC ASSESSMENT IN OVERWEIGHT PATIENTS WITH AND WITHOUT HYPERPROLACTINEMIA CAUSED BY PROLACTINOMA.
Breyer Freitas B; Rothen RE; Zeni D; Garcia Soares Leães C; Costa Oliveira M; Michielin Busnello F; Fernanda Semmelmann Pereira-Lima J
Nutr Hosp; 2015 Nov; 32(5):2030-7. PubMed ID: 26545657
[TBL] [Abstract][Full Text] [Related]
60. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
Lebbe M; Hubinont C; Bernard P; Maiter D
Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
